Insider trade

CEO received an award of 130.07 ELAN derivative securities

Traded Dec 12, 2025 · Filed Dec 16, 2025

ElancoELAN

130.07
Derivative units · @ $21.29

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 12, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 16, 2025

CEOGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001479079-25-000019
Filed / recorded

Dec 16, 2025, 9:41 PM UTC

Added to OQRO

Oct 6, 2026, 7:37 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Elanco Animal Health Inc

Issuer CIK

1739104

Ticker

ELAN

Reporting person

Jeffrey N Simmons

Relationship

Director, Officer

Officer title

PRESIDENT, CEO AND DIRECTOR

Security

Deferred Stock Units

Table

Derivative (Table II)

Transaction date

Dec 12, 2025

Transaction code

A

Shares / units

130.0723

Price per share

$21.29

Acquired / disposed

Acquired (A)

Shares owned after

18,604.9984

Ownership form

Direct

Amendment

No

Footnotes from the filing

Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.